Cancer stem cells in lung cancer: Evidence and controversies

Respirology

Volumn 18, Issue 5, 2013, Pages 757-764

  Alamgeer, Muhammad ^a,b   Peacock, Craig D ^c   Matsui, William ^c   Ganju, Vinod ^a,b   Watkins, D Neil ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

aldehyde dehydrogenase; cancer stem cell; lung cancer; side population

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; BETA CATENIN; CD133 ANTIGEN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; NOTCH RECEPTOR; NOTCH3 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; SONIC HEDGEHOG PROTEIN; STROMELYSIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; TRANSCRIPTION FACTOR NANOG; UROKINASE; WNT PROTEIN; WNT2 PROTEIN;

ANTIANGIOGENIC ACTIVITY; ASYMMETRIC CELL DIVISION; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CARCINOGENICITY; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL ISOLATION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DETOXIFICATION; EMBRYONIC STEM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL NICHE; TREATMENT RESPONSE; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

ANTIGENS, CD; ANTIGENS, CD44; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PEPTIDES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84879341208     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12094     Document Type: Review

References (87)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA 2011; 61: 69-90.
2. Wu K, House L, Liu W, et al. Personalized targeted therapy for lung cancer. Int. J. Mol. Sci. 2012; 13: 11471-11496.
3. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009; 115: 5218-5227.
4. Wisnivesky JP, Yankelevitz D, Henschke CI,. Stage of lung cancer in relation to its size: part 2. Evidence. Chest 2005; 127: 1136-1139.
5. Howlader N, Noon AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD, 2012. based on November 2011 SEER data submission, posted to the SEER web site. [Accessed 2 Jan 2013.] Available from URL: http://seer.cancer.gov/csr/1975-2009- pops09/
6. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: e73.
7. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012; 4: 120ra17.
8. Janne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95: 1528-1538.
9. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1993; 11: 336-344.
10. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
11. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U S A 2003; 100: 3983-3988.
13. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
14. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
15. Pastrana E, Silva-Vargas V, Doetsch F,. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011; 8: 486-498.
16. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997; 3: 730-737.
17. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67: 4827-4833.
18. Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008; 3: e3077.
19. Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 2008; 3: e2637.
20. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008; 15: 504-514.
21. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U S A 2009; 106: 16281-16286.
22. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009; 7: 330-338.
23. Shi Y, Fu X, Hua Y, et al. The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS ONE 2012; 7: e33358.
24. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
25. Ishizawa K, Rasheed ZA, Karisch R, et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010; 7: 279-282.
26. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996; 183: 1797-1806.
27. Zhong Y, Zhou C, Ma W, et al. Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342. Biochem. Biophys. Res. Commun. 2007; 364: 338-343.
28. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U S A 2006; 103: 11707-11712.
29. Kastan MB, Schlaffer E, Russo JE, et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 1947-1950.
30. Moreb JS,. Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 2008; 3: 237-246.
31. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
32. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
33. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021.
34. Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004; 117: 3539-3545.
35. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006; 107: 2162-2169.
36. Marhaba R, Zoller M,. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 2004; 35: 211-231.
37. Carney DN, Gazdar AF, Bunn PA, Jr, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells 1982; 1: 149-164.
38. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE 2010; 5: e14062.
39. Qiu X, Wang Z, Li Y, et al. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett. 2012; 323: 161-170.
40. Gutova M, Najbauer J, Gevorgyan A, et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007; 2: e243.
41. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010; 70: 9937-9948.
42. al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer 2008; 7: 87. doi: 10.1186/1476-4598-7-87.
43. Woo T, Okudela K, Mitsui H, et al. Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol. 2010; 4: 32-42.
44. Salnikov AV, Gladkich J, Moldenhauer G, et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int. J. Cancer 2010; 126: 950-958.
45. Li X, Wan L, Geng J, et al. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J. Thorac. Oncol. 2012; 7: 1235-1245.
46. Dimou A, Neumeister V, Agarwal S, et al. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer. Am. J. Pathol. 2012; 181: 1436-1442.
47. Karamboulas C, Ailles L,. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 2013; 1830: 2481-2495.
48. Takebe N, Ivy SP,. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin. Cancer Res. 2010; 16: 3106-3112.
49. Tian F, Mysliwietz J, Ellwart J, et al. Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations. Clin. Exp. Med. 2012; 12: 25-30.
50. Konishi J, Kawaguchi KS, Vo H, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007; 67: 8051-8057.
51. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6: 7-14.
52. Varjosalo M, Taipale J,. Hedgehog: functions and mechanisms. Genes Dev. 2008; 22: 2454-2472.
53. Sasaki H, Nishizaki Y, Hui C, et al. Regulation of GLI2 and GLI3 activities by an amino-terminal repression domain: implication of GLI2 and GLI3 as primary mediators of Shh signaling. Development 1999; 126: 3915-3924.
54. Clement V, Sanchez P, de Tribolet N, et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 2007; 17: 165-172.
55. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. U S A 2007; 104: 4048-4053.
56. Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. U S A 2007; 104: 5895-5900.
57. Mukherjee S, Frolova N, Sadlonova A, et al. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol. Ther. 2006; 5: 674-683.
58. Yuan Z, Goetz JA, Singh S, et al. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 2007; 26: 1046-1055.
59. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422: 313-317.
60. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med. 2011; 17: 1504-1508.
61. Artavanis-Tsakonas S, Rand MD, Lake RJ,. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
62. Collins BJ, Kleeberger W, Ball DW,. Notch in lung development and lung cancer. Semin. Cancer Biol. 2004; 14: 357-364.
63. Richter S, McWhirter E, Chen EX, et al,. A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine, in patients with advanced solid tumors (PHL-078/CTEP 8575). J. Clin. Oncol. 2012; 30: Suppl; Abstr 3082.
64. Tawbi HA, Ahnert R, Thomas AL, Shou GY, et al,. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacoynamic correlation. J. Clin. Oncol. 2011; 29: Suppl; Abstr 3062.
65. Ito T, Udaka N, Yazawa T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000; 127: 3913-3921.
66. Dang TP, Eichenberger S, Gonzalez A, et al. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 2003; 22: 1988-1997.
67. Chen H, Thiagalingam A, Chopra H, et al. Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc. Natl. Acad. Sci. U S A 1997; 94: 5355-5360.
68. Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, et al. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol. Cancer Res. 2011; 9: 1746-1754.
69. Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002; 8: 979-986.
70. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66: 7445-7452.
71. Westhoff B, Colaluca IN, D'Ario G, et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. U S A 2009; 106: 22293-22298.
72. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003; 33: 416-421.
73. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011; 473: 230-233.
74. Liu Z, Turkoz A, Jackson EN, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J. Clin. Invest. 2011; 121: 800-808.
75. Phng LK, Gerhardt H,. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009; 16: 196-208.
76. Radtke F, Fasnacht N, Macdonald HR,. Notch signaling in the immune system. Immunity 2010; 32: 14-27.
77. Imbimbo BP,. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr. Top. Med. Chem. 2008; 8: 54-61.
78. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003; 22: 7218-7221.
79. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004; 23: 6170-6174.
80. Moreb JS, Zucali JR, Ostmark B, et al. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin. Cytom. 2007; 72: 281-289.
81. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer 2011; 11: 340. doi: 10.1186/1471-2407-11-340.
82. Akunuru S, James Zhai Q, Zheng Y,. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 2012; 3: e352.
83. Meng X, Li M, Wang X, et al. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2009; 100: 1040-1046.
84. Ucar D, Cogle CR, Zucali JR, et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact. 2009; 178: 48-55.
85. Akunuru S, Palumbo J, Zhai QJ, et al. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS ONE 2011; 6: e16951.
86. Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-644.
87. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-349.